Erlotinib Hydrochloride



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 59.6%
Non-small Cell Lung Cancer 10.9%
Lung Carcinoma Cell Type Unspecified Stage 0 6.9%
Lung Neoplasm Malignant 4.2%
Pancreatic Carcinoma 4.0%
Hepatic Neoplasm Malignant 2.5%
Adenocarcinoma Pancreas 2.3%
Lung Adenocarcinoma 2.0%
Pancreatic Carcinoma Metastatic 1.2%
Hypertension 1.0%
Pain 0.9%
Nausea 0.8%
Non-small Cell Lung Cancer Metastatic 0.7%
Vomiting 0.5%
Diabetes Mellitus 0.5%
Diarrhoea 0.5%
Constipation 0.5%
Rash 0.4%
Colorectal Cancer Metastatic 0.4%
Lung Squamous Cell Carcinoma Stage Unspecified 0.4%
Death 44.7%
Neoplasm Malignant 7.3%
Rash 5.3%
Diarrhoea 4.8%
Incorrect Dose Administered 4.7%
Pneumonia 3.5%
Hospitalisation 3.1%
Vomiting 3.0%
Anaemia 2.7%
Pulmonary Embolism 2.7%
Dyspnoea 2.4%
Disease Progression 2.1%
Off Label Use 2.1%
Pleural Effusion 1.8%
Nausea 1.7%
Respiratory Failure 1.7%
Non-small Cell Lung Cancer 1.6%
Fatigue 1.6%
Pyrexia 1.6%
Thrombocytopenia 1.6%
Secondary
Product Used For Unknown Indication 37.3%
Hepatic Neoplasm Malignant 9.6%
Non-small Cell Lung Cancer 7.7%
Ascites 5.2%
Hypertension 3.9%
Diarrhoea 3.8%
Chronic Obstructive Pulmonary Disease 3.6%
Muscle Spasms 3.2%
Enteritis 3.1%
Diabetes Mellitus 2.9%
Prophylaxis 2.7%
Pancreatic Carcinoma 2.4%
Insomnia 2.3%
Nausea 2.1%
Pain 1.9%
Lung Neoplasm Malignant 1.8%
Vomiting 1.7%
Unevaluable Event 1.6%
Anxiety Disorder 1.6%
Adenocarcinoma Pancreas 1.5%
Diarrhoea 10.4%
Death 9.4%
Oedema Peripheral 7.6%
Rash 7.6%
Dyspnoea 7.0%
Anaemia 6.3%
Off Label Use 5.3%
Vomiting 5.1%
Epistaxis 4.7%
General Physical Health Deterioration 4.5%
Haemorrhagic Anaemia 3.7%
Hyperkalaemia 3.7%
Interstitial Lung Disease 3.7%
Toxicity To Various Agents 3.7%
Pneumonia 3.5%
Dehydration 2.9%
Pyrexia 2.9%
Urinary Tract Infection 2.9%
Ascites 2.7%
Neoplasm Malignant 2.7%
Concomitant
Pancreatic Carcinoma 12.2%
Non-small Cell Lung Cancer 11.5%
Breast Cancer Metastatic 9.4%
Drug Use For Unknown Indication 8.6%
Pancreatic Carcinoma Metastatic 7.9%
Adenocarcinoma Pancreas 7.6%
Lung Neoplasm Malignant 7.6%
Pain 7.6%
Product Used For Unknown Indication 5.8%
Lung Adenocarcinoma 4.7%
Hepatic Neoplasm Malignant 2.2%
Hypertension 2.2%
Cardiomyopathy 1.8%
Gastrooesophageal Reflux Disease 1.8%
Metastatic Renal Cell Carcinoma 1.8%
Nausea 1.8%
Constipation 1.4%
Deep Vein Thrombosis 1.4%
Glioma 1.4%
Pancreatic Carcinoma Non-resectable 1.4%
Renal Failure 14.3%
Gastrointestinal Toxicity 12.7%
Death 7.9%
Neoplasm Progression 6.3%
Thrombosis 6.3%
Dehydration 4.8%
Interstitial Lung Disease 4.8%
Rash 4.8%
Recurrent Cancer 4.8%
Vomiting 4.8%
Weight Bearing Difficulty 4.8%
Drug Dose Omission 3.2%
Hepatic Neoplasm Malignant 3.2%
Osteonecrosis Of Jaw 3.2%
Rectal Haemorrhage 3.2%
Small Intestinal Haemorrhage 3.2%
Toothache 3.2%
Acute Respiratory Failure 1.6%
Arthritis 1.6%
Aspartate Aminotransferase Increased 1.6%
Interacting
Product Used For Unknown Indication 52.4%
Lung Neoplasm Malignant 13.3%
Cancer Pain 7.8%
Pain 6.6%
Bronchopneumonia 4.8%
Chemotherapy 2.4%
Dyslipidaemia 2.4%
Lung Adenocarcinoma 2.4%
Non-small Cell Lung Cancer Stage Iiib 1.8%
Premedication 1.8%
Diarrhoea 1.2%
Non-small Cell Lung Cancer 1.2%
Antibiotic Therapy 0.6%
Embolism Venous 0.6%
Radiotherapy 0.6%
Drug Interaction 31.6%
Rash 31.6%
Drug Level Decreased 13.2%
Somnolence 7.9%
Swelling 5.3%
Cardiac Failure 2.6%
Contusion 2.6%
Death 2.6%
Interstitial Lung Disease 2.6%